CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2...
7 insider purchases on record · latest filing 2026-06-29.
Insiders have also filed 42 sale transactions at CGON.